Skip to main content
. 2020 Jan 3;35(4):515–520. doi: 10.46497/ArchRheumatol.2020.7795

Table 1. Clinical data of study group (n=30).

  n % Mean±SD
Subgroup      
Limited 18    
Diffuse disease 12    
ANA positive 24 80  
Anti centromere positive 8 27  
Anti Scl-70 positive 10 33  
Diagnostic NVC (n=21) 19 90  
Organ involvement      
Gastrointestinal 23 76  
Lung 21 70  
Heart 19 63  
Kidney 0 0  
mRodnan     13.8±6.2
SD: Standard deviation; ANA: Antinuclear antibody; Anti Scl-70: Anti- topoisomerase I after type I topoisomerase target; NVC: Nailfold video capillaroscopy.